Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1186/s13045-024-01529-6.

Title:
FFAR2 expressing myeloid-derived suppressor cells drive cancer immunoevasion | Journal of Hematology & Oncology
Description:
Background Emerging evidences suggest that aberrant metabolites contributes to the immunosuppressive microenvironment that leads to cancer immune evasion. Among tumor immunosuppressive cells, myeloid-derived suppressor cells (MDSCs) are pathologically activated and extremely immunosuppressive, which are closely associated with poor clinical outcomes of cancer patients. However, the correlation between MDSCs mediated immunosuppression and particular cancer metabolism remained elusive. Methods Spontaneous lung adenocarcinoma and subcutaneous mouse tumor models, gas chromatography–mass spectrometry (GC–MS) and immunofluorescence assay of patient-derived lung adenocarcinoma tissues, and flow cytometry, RNA sequencing and Western blotting of immune cells, were utilized. Results Metabolite profiling revealed a significant accumulation of acetic acids in tumor tissues from both patients and mouse model, which contribute to immune suppression and cancer progression significantly through free fatty acid receptor 2 (FFAR2). Furthermore, FFAR2 is highly expressed in the myeloid-derived suppressor cells (MDSCs) from the tumor of lung adenocarcinoma (LUAD) patients which is greatly associated with poor prognosis. Surprisingly, whole or myeloid Ffar2 gene deletion markedly inhibited urethane-induced lung carcinogenesis and syngeneic tumor growth with reduced MDSCs and increased CD8+ T cell infiltration. Mechanistically, FFAR2 deficiency in MDSCs significantly reduced the expression of Arg1 through Gαq/Calcium/PPAR-γ axis, which eliminated T cell dysfunction through relieving L-Arginine consumption in tumor microenvironment. Therefore, replenishment of L-Arginine or inhibition to PPAR-γ restored acetic acids/FFAR2 mediated suppression to T cells significantly. Finally, FFAR2 inhibition overcame resistance to immune checkpoint blockade through enhancing the recruitment and cytotoxicity of tumor-infiltrating T cells. Conclusion Altogether, our results demonstrate that the acetic acids/FFAR2 axis enhances MDSCs mediated immunosuppression through Gαq/calcium/PPAR-γ/Arg1 signaling pathway, thus contributing to cancer progression. Therefore, FFAR2 may serve as a potential new target to eliminate pathologically activated MDSCs and reverse immunosuppressive tumor microenvironment, which has great potential in improving clinical outcomes of cancer immunotherapy.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Science
  • Health & Fitness
  • Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 7,625,932 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

ffar, tumor, cells, mdscs, mice, cell, llc, fig, cancer, lung, pubmed, article, biological, tumors, replicates, immune, mouse, google, scholar, expression, tissues, acids, arg, additional, fatty, file, growth, cas, significantly, larginine, clone, microenvironment, shown, analyzed, antimouse, representative, purchased, inhibitor, central, data, acetic, injected, flow, cytometry, normal, adenocarcinoma, acid, myeloid, scfas, human,

Topics {✒️}

gαq/calcium/ppar-γ/arg1 signaling pathway bv421-conjugated anti-mouse ly-6g pe/cyanine7-conjugated anti-mouse f4/80 gαq/calcium/ppar-γ signaling pathway apc-conjugated anti-mouse ly-6c pe/cyanine7-conjugated anti-mouse il-10 gαq/calcium/ppar-γ/arg1 signaling ccaat/enhancer-binding protein-β pe-conjugated anti-mouse cd8a apc-conjugated anti-mouse cd3 fitc-conjugated anti-mouse cd8a fitc-conjugated anti-mouse cd11b quantitative real-time rt-pcr cd11b+ly-6chigh-m-mdsc cd11b+ly-6g+-pmn-mdsc granulocyte-macrophage colony-stimulating factor pe-conjugated anti-mouse cd11c fitc-conjugated anti-mouse cd45 gαq/calcium/ppar-γ axis cd11b+ly-6chigh-m-mdscs cd11b+ly-6g+-pmn-mdscs crispr–cas9 genome-editing system invivomab anti-mouse ly6g/ly6c modulators targeting calcium/ppar-γ pe-conjugated anti-mouse ifnγ pe-conjugated anti-mouse inos cd11b+gr-1high-pmn-mdscs tumor-infiltrating cd11b+gr-1+-mdsc myeloid-derived suppressor cells gas chromatography–mass spectrometry urethane-induced lung cancer cd11b+gr-1−-f4/80+-macrophage ppar-γ signaling pathway calcium/ppar-γ pathway real-time rt-pcr short-chain fatty acids bone marrow-derived mdscs urethane-induced tumor nodules ffar2 inhibitor + anti-pd1 antibody article download pdf tims including cd11c+mhcii+-dcs urethane-induced lung tumors anti-gr-1 antibody treatment invivomab anti-mouse pd-1 cytofix/cytoperm soln kit tumor cell-derived cytokines analyze tumor-infiltrating leukocytes important metabolite-sensing receptor cd11b+gr-1−f4/80+-tams pd-1/pd-l1 blockade

Questions {❓}

  • The Warburg effect: how does it benefit cancer cells?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:FFAR2 expressing myeloid-derived suppressor cells drive cancer immunoevasion
         description:Emerging evidences suggest that aberrant metabolites contributes to the immunosuppressive microenvironment that leads to cancer immune evasion. Among tumor immunosuppressive cells, myeloid-derived suppressor cells (MDSCs) are pathologically activated and extremely immunosuppressive, which are closely associated with poor clinical outcomes of cancer patients. However, the correlation between MDSCs mediated immunosuppression and particular cancer metabolism remained elusive. Spontaneous lung adenocarcinoma and subcutaneous mouse tumor models, gas chromatography–mass spectrometry (GC–MS) and immunofluorescence assay of patient-derived lung adenocarcinoma tissues, and flow cytometry, RNA sequencing and Western blotting of immune cells, were utilized. Metabolite profiling revealed a significant accumulation of acetic acids in tumor tissues from both patients and mouse model, which contribute to immune suppression and cancer progression significantly through free fatty acid receptor 2 (FFAR2). Furthermore, FFAR2 is highly expressed in the myeloid-derived suppressor cells (MDSCs) from the tumor of lung adenocarcinoma (LUAD) patients which is greatly associated with poor prognosis. Surprisingly, whole or myeloid Ffar2 gene deletion markedly inhibited urethane-induced lung carcinogenesis and syngeneic tumor growth with reduced MDSCs and increased CD8+ T cell infiltration. Mechanistically, FFAR2 deficiency in MDSCs significantly reduced the expression of Arg1 through Gαq/Calcium/PPAR-γ axis, which eliminated T cell dysfunction through relieving L-Arginine consumption in tumor microenvironment. Therefore, replenishment of L-Arginine or inhibition to PPAR-γ restored acetic acids/FFAR2 mediated suppression to T cells significantly. Finally, FFAR2 inhibition overcame resistance to immune checkpoint blockade through enhancing the recruitment and cytotoxicity of tumor-infiltrating T cells. Altogether, our results demonstrate that the acetic acids/FFAR2 axis enhances MDSCs mediated immunosuppression through Gαq/calcium/PPAR-γ/Arg1 signaling pathway, thus contributing to cancer progression. Therefore, FFAR2 may serve as a potential new target to eliminate pathologically activated MDSCs and reverse immunosuppressive tumor microenvironment, which has great potential in improving clinical outcomes of cancer immunotherapy.
         datePublished:2024-02-24T00:00:00Z
         dateModified:2024-02-24T00:00:00Z
         pageStart:1
         pageEnd:20
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s13045-024-01529-6
         keywords:
            SCFAs
            FFAR2
            MDSCs
            Immune evasion
            Immunotherapy
            Oncology
            Hematology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-024-01529-6/MediaObjects/13045_2024_1529_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-024-01529-6/MediaObjects/13045_2024_1529_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-024-01529-6/MediaObjects/13045_2024_1529_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-024-01529-6/MediaObjects/13045_2024_1529_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-024-01529-6/MediaObjects/13045_2024_1529_Fig5_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-024-01529-6/MediaObjects/13045_2024_1529_Fig6_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-024-01529-6/MediaObjects/13045_2024_1529_Fig7_HTML.png
         isPartOf:
            name:Journal of Hematology & Oncology
            issn:
               1756-8722
            volumeNumber:17
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Zeda Zhao
               affiliation:
                     name:East China Normal University
                     address:
                        name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Juliang Qin
               affiliation:
                     name:East China Normal University
                     address:
                        name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ying Qian
               affiliation:
                     name:East China Normal University
                     address:
                        name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Chenshen Huang
               affiliation:
                     name:Fujian Provincial Hospital
                     address:
                        name:Fujian Provincial Hospital, Fuzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Xiaohong Liu
               affiliation:
                     name:East China Normal University
                     address:
                        name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ning Wang
               affiliation:
                     name:Affiliated Hospital of Zhejiang University
                     address:
                        name:Huzhou Central Hospital, Affiliated Hospital of Zhejiang University, Zhejiang, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Liqin Li
               affiliation:
                     name:Affiliated Hospital of Zhejiang University
                     address:
                        name:Huzhou Central Hospital, Affiliated Hospital of Zhejiang University, Zhejiang, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yuqing Chao
               affiliation:
                     name:East China Normal University
                     address:
                        name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Binghe Tan
               affiliation:
                     name:BRL Medicine Inc.
                     address:
                        name:BRL Medicine Inc., Shanghai, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Na Zhang
               affiliation:
                     name:BRL Medicine Inc.
                     address:
                        name:BRL Medicine Inc., Shanghai, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Min Qian
               affiliation:
                     name:East China Normal University
                     address:
                        name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Dali Li
               affiliation:
                     name:East China Normal University
                     address:
                        name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mingyao Liu
               affiliation:
                     name:East China Normal University
                     address:
                        name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Bing Du
               affiliation:
                     name:East China Normal University
                     address:
                        name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:FFAR2 expressing myeloid-derived suppressor cells drive cancer immunoevasion
      description:Emerging evidences suggest that aberrant metabolites contributes to the immunosuppressive microenvironment that leads to cancer immune evasion. Among tumor immunosuppressive cells, myeloid-derived suppressor cells (MDSCs) are pathologically activated and extremely immunosuppressive, which are closely associated with poor clinical outcomes of cancer patients. However, the correlation between MDSCs mediated immunosuppression and particular cancer metabolism remained elusive. Spontaneous lung adenocarcinoma and subcutaneous mouse tumor models, gas chromatography–mass spectrometry (GC–MS) and immunofluorescence assay of patient-derived lung adenocarcinoma tissues, and flow cytometry, RNA sequencing and Western blotting of immune cells, were utilized. Metabolite profiling revealed a significant accumulation of acetic acids in tumor tissues from both patients and mouse model, which contribute to immune suppression and cancer progression significantly through free fatty acid receptor 2 (FFAR2). Furthermore, FFAR2 is highly expressed in the myeloid-derived suppressor cells (MDSCs) from the tumor of lung adenocarcinoma (LUAD) patients which is greatly associated with poor prognosis. Surprisingly, whole or myeloid Ffar2 gene deletion markedly inhibited urethane-induced lung carcinogenesis and syngeneic tumor growth with reduced MDSCs and increased CD8+ T cell infiltration. Mechanistically, FFAR2 deficiency in MDSCs significantly reduced the expression of Arg1 through Gαq/Calcium/PPAR-γ axis, which eliminated T cell dysfunction through relieving L-Arginine consumption in tumor microenvironment. Therefore, replenishment of L-Arginine or inhibition to PPAR-γ restored acetic acids/FFAR2 mediated suppression to T cells significantly. Finally, FFAR2 inhibition overcame resistance to immune checkpoint blockade through enhancing the recruitment and cytotoxicity of tumor-infiltrating T cells. Altogether, our results demonstrate that the acetic acids/FFAR2 axis enhances MDSCs mediated immunosuppression through Gαq/calcium/PPAR-γ/Arg1 signaling pathway, thus contributing to cancer progression. Therefore, FFAR2 may serve as a potential new target to eliminate pathologically activated MDSCs and reverse immunosuppressive tumor microenvironment, which has great potential in improving clinical outcomes of cancer immunotherapy.
      datePublished:2024-02-24T00:00:00Z
      dateModified:2024-02-24T00:00:00Z
      pageStart:1
      pageEnd:20
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s13045-024-01529-6
      keywords:
         SCFAs
         FFAR2
         MDSCs
         Immune evasion
         Immunotherapy
         Oncology
         Hematology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-024-01529-6/MediaObjects/13045_2024_1529_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-024-01529-6/MediaObjects/13045_2024_1529_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-024-01529-6/MediaObjects/13045_2024_1529_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-024-01529-6/MediaObjects/13045_2024_1529_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-024-01529-6/MediaObjects/13045_2024_1529_Fig5_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-024-01529-6/MediaObjects/13045_2024_1529_Fig6_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-024-01529-6/MediaObjects/13045_2024_1529_Fig7_HTML.png
      isPartOf:
         name:Journal of Hematology & Oncology
         issn:
            1756-8722
         volumeNumber:17
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Zeda Zhao
            affiliation:
                  name:East China Normal University
                  address:
                     name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Juliang Qin
            affiliation:
                  name:East China Normal University
                  address:
                     name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ying Qian
            affiliation:
                  name:East China Normal University
                  address:
                     name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Chenshen Huang
            affiliation:
                  name:Fujian Provincial Hospital
                  address:
                     name:Fujian Provincial Hospital, Fuzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Xiaohong Liu
            affiliation:
                  name:East China Normal University
                  address:
                     name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ning Wang
            affiliation:
                  name:Affiliated Hospital of Zhejiang University
                  address:
                     name:Huzhou Central Hospital, Affiliated Hospital of Zhejiang University, Zhejiang, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Liqin Li
            affiliation:
                  name:Affiliated Hospital of Zhejiang University
                  address:
                     name:Huzhou Central Hospital, Affiliated Hospital of Zhejiang University, Zhejiang, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yuqing Chao
            affiliation:
                  name:East China Normal University
                  address:
                     name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Binghe Tan
            affiliation:
                  name:BRL Medicine Inc.
                  address:
                     name:BRL Medicine Inc., Shanghai, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Na Zhang
            affiliation:
                  name:BRL Medicine Inc.
                  address:
                     name:BRL Medicine Inc., Shanghai, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Min Qian
            affiliation:
                  name:East China Normal University
                  address:
                     name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Dali Li
            affiliation:
                  name:East China Normal University
                  address:
                     name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mingyao Liu
            affiliation:
                  name:East China Normal University
                  address:
                     name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Bing Du
            affiliation:
                  name:East China Normal University
                  address:
                     name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Journal of Hematology & Oncology
      issn:
         1756-8722
      volumeNumber:17
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:East China Normal University
      address:
         name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
         type:PostalAddress
      name:East China Normal University
      address:
         name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
         type:PostalAddress
      name:East China Normal University
      address:
         name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
         type:PostalAddress
      name:Fujian Provincial Hospital
      address:
         name:Fujian Provincial Hospital, Fuzhou, China
         type:PostalAddress
      name:East China Normal University
      address:
         name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
         type:PostalAddress
      name:Affiliated Hospital of Zhejiang University
      address:
         name:Huzhou Central Hospital, Affiliated Hospital of Zhejiang University, Zhejiang, China
         type:PostalAddress
      name:Affiliated Hospital of Zhejiang University
      address:
         name:Huzhou Central Hospital, Affiliated Hospital of Zhejiang University, Zhejiang, China
         type:PostalAddress
      name:East China Normal University
      address:
         name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
         type:PostalAddress
      name:BRL Medicine Inc.
      address:
         name:BRL Medicine Inc., Shanghai, China
         type:PostalAddress
      name:BRL Medicine Inc.
      address:
         name:BRL Medicine Inc., Shanghai, China
         type:PostalAddress
      name:East China Normal University
      address:
         name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
         type:PostalAddress
      name:East China Normal University
      address:
         name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
         type:PostalAddress
      name:East China Normal University
      address:
         name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
         type:PostalAddress
      name:East China Normal University
      address:
         name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Zeda Zhao
      affiliation:
            name:East China Normal University
            address:
               name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
               type:PostalAddress
            type:Organization
      name:Juliang Qin
      affiliation:
            name:East China Normal University
            address:
               name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
               type:PostalAddress
            type:Organization
      name:Ying Qian
      affiliation:
            name:East China Normal University
            address:
               name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
               type:PostalAddress
            type:Organization
      name:Chenshen Huang
      affiliation:
            name:Fujian Provincial Hospital
            address:
               name:Fujian Provincial Hospital, Fuzhou, China
               type:PostalAddress
            type:Organization
      name:Xiaohong Liu
      affiliation:
            name:East China Normal University
            address:
               name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
               type:PostalAddress
            type:Organization
      name:Ning Wang
      affiliation:
            name:Affiliated Hospital of Zhejiang University
            address:
               name:Huzhou Central Hospital, Affiliated Hospital of Zhejiang University, Zhejiang, China
               type:PostalAddress
            type:Organization
      name:Liqin Li
      affiliation:
            name:Affiliated Hospital of Zhejiang University
            address:
               name:Huzhou Central Hospital, Affiliated Hospital of Zhejiang University, Zhejiang, China
               type:PostalAddress
            type:Organization
      name:Yuqing Chao
      affiliation:
            name:East China Normal University
            address:
               name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
               type:PostalAddress
            type:Organization
      name:Binghe Tan
      affiliation:
            name:BRL Medicine Inc.
            address:
               name:BRL Medicine Inc., Shanghai, China
               type:PostalAddress
            type:Organization
      name:Na Zhang
      affiliation:
            name:BRL Medicine Inc.
            address:
               name:BRL Medicine Inc., Shanghai, China
               type:PostalAddress
            type:Organization
      name:Min Qian
      affiliation:
            name:East China Normal University
            address:
               name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
               type:PostalAddress
            type:Organization
      name:Dali Li
      affiliation:
            name:East China Normal University
            address:
               name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
               type:PostalAddress
            type:Organization
      name:Mingyao Liu
      affiliation:
            name:East China Normal University
            address:
               name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
               type:PostalAddress
            type:Organization
      name:Bing Du
      affiliation:
            name:East China Normal University
            address:
               name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
      name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
      name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
      name:Fujian Provincial Hospital, Fuzhou, China
      name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
      name:Huzhou Central Hospital, Affiliated Hospital of Zhejiang University, Zhejiang, China
      name:Huzhou Central Hospital, Affiliated Hospital of Zhejiang University, Zhejiang, China
      name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
      name:BRL Medicine Inc., Shanghai, China
      name:BRL Medicine Inc., Shanghai, China
      name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
      name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
      name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
      name:Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China

External Links {🔗}(191)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

5.62s.